Jimandin (Sitagliptin)

Sitagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition raises levels of the incretin hormones GLP‑1 and GIP, leading to glucose‑dependent insulin secretion and reduced glucagon release, thereby lowering blood glucose concentrations.

The dosage of sitagliptin is individualized. The prescribing healthcare professional determines the appropriate amount based on the patient’s renal function, concomitant therapies and glycaemic targets. No fixed regimen is provided here.

Safety data for sitagliptin in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To request Jimandin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, sitagliptin has a lower intrinsic risk of hypoglycaemia because its glucose‑dependent mechanism requires elevated blood glucose to stimulate insulin. Unlike metformin, it does not affect gastrointestinal absorption and can be used when metformin is contraindicated, though overall glucose‑lowering efficacy may be modest.

Jimandin tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Jimandin is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

The most serious adverse events reported with sitagliptin include acute pancreatitis, severe hypersensitivity reactions such as anaphylaxis, and rare skin disorders like bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, swelling, rash or breathing difficulties.

Jimandin is contraindicated in patients with a known hypersensitivity to sitagliptin or any component of the formulation. Caution is also advised for individuals with severe renal impairment, a history of pancreatitis, or those taking medications that may cause significant drug‑drug interactions.